Thursday, Sep 27, 2018 8:00a -
Friday, Sep 28, 2018 4:00p
Wyndham Boston Beacon Hill
5 Blossom Street
Boston, MA 02114
Lectures & Conferences
With the US in the midst of an opioid crisis, it has never been more critical for the pharmaceutical, biotechnology and academic fields to unite in a common goal to innovate and accelerate the discovery and development of novel non-opioid therapies to treat pain.
This summit and its expert speaker faculty will update you on the latest and novel RandD efforts currently ongoing in discovery and optimization of non-opioid analgesic targets and their mechanism of action. In addition, the inaugural Non-Opioid Pain Drug Development Summit will be your dedicated platform to overcome translational challenges such as animal model predictive value, biomarker identification, and proving efficacy against placebo effect.
September 27-28, 2018
+ 1 617 455 4188
Conference + 1 Workshop Earlybird (Book by 15/06/18): USD 1798.0,
Conference + 1 Workshop (standard rate): USD 2498.0,
Conference Earlybird (Book by 15/06/18): USD 1299.0,
Conference (Standard rate): USD 1999.0,
Workshop: USD 499.0
Speakers: Mary Ann Pellymounter (NIH/NINDS/Division of Translational Research), Daniel Klamer (Anavex Life Sciences Corp.), Kerrie Brady (Centrexion Corp), Crist Frangaki (Achelios Therapeutics), Lucio Rovati (Rottapharm Biotech), Silviu Itescu (Mesoblast Ltd.)